Withdrawal of Atezolizumab's Indication for Metastatic Triple-Negative Breast Cancer

This week, we’re reviewing the details of Genentech’s decision to withdraw atezolizumab’s U.S. indication for metastatic triple-negative breast cancer. We’ll then hear about a systematic review and meta-analysis that provided a profile of treatment-related adverse events observed in clinical trials combining PD-1 or PD-L1 inhibitors with chemotherapy, targeted therapy, immunotherapy, and radiotherapy.

---